Clinical Trial Update: Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and efficacy of STALORAL Birch 300 IR in children with birch pollen-induced allergic rhinoconjunctivitis without asthma; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinoconjunctivitis
• Birch Pollen Allergy

Drugs mentioned

• STALORAL Birch 300 IR (birch pollen extract)

Snippet

Sponsor: Stallergenes Greer | Conditions: Allergic Rhinoconjunctivitis, Birch Pollen Allergy | Phase 3 | Status: COMPLETED